BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26400354)

  • 1. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
    Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
    Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
    Cao ZH; Yin HP; Jiang N; Yu B
    Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y; Wu Y; Li W; Kong Z; Zou X
    Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
    Ji WP; He NB
    Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
    Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
    BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
    Zhang H; Ge J; Hong H; Bi L; Sun Z
    World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.
    Hao T; Feng W; Zhang J; Sun YJ; Wang G
    Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
    Yang LM; Li XH; Bao CF
    Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.
    Wang MJ; Zhu Y; Guo XJ; Tian ZZ
    Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
    Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
    Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
    Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
    Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.
    Chen XJ; Tong ZC; Kang X; Wang ZC; Huang GL; Yang TM; Dong L
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6658-6666. PubMed ID: 30402838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma.
    Liu ZF; Asila AL; Aikenmu K; Zhao J; Meng QC; Fang R
    Genet Mol Res; 2015 Oct; 14(4):12967-72. PubMed ID: 26505449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.
    Zhao F; Shang Y; Zeng C; Gao D; Li K
    Int J Clin Exp Pathol; 2015; 8(9):11579-86. PubMed ID: 26617894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
    Shi ZH; Shi GY; Liu LG
    Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer.
    Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ERCC gene polymorphism with osteosarcoma risk.
    Wang G; Li J; Xu X; Gupta RK; Gao X
    Afr Health Sci; 2020 Dec; 20(4):1840-1848. PubMed ID: 34394247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.